Pancreatic Cancer Research

Clinical trialPhase 2 / Phase 3Suspended

Acelarin First Line Randomised Pancreatic Study

A Phase III, Open Label, Multicentre Randomised Clinical Study Comparing Acelarin (NUC-1031) With Gemcitabine in Patients With Metastatic Pancreatic Carcinoma

NCT03610100↗ ClinicalTrials.gov, retrieved 4 November 2026

Outcome
Stopped earlySuspended to recruitment following TSC review on efficacy and toxicities (Toxicity)
Phase
Phase 2 / Phase 3
Status
Suspended
Study type
Interventional
Start
December 2015
Expected end
December 2022
Enrollment
328 participants
Sites
1
Primary outcomes
Number of participants that have survived throughout treatment and also into follow-up, as measured by the primary cause of death and date of death CRFs.
Sponsor
Other
Results posted
No
Last update
29 October 2019

These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.

Try

Papers 5